Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 601–700 of 991
Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients
Liu, J., Ma, J., Xing, N., Ji, Z., Li, J., Zhang, S., & Guo, Z. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04201-z · Cited by 13
Training the microbiota to increase immune checkpoint blockade and to reduce toxicity
Rescigno, M. (2023) · European Journal of Immunology · doi:10.1002/eji.202250183 · Cited by 15
“In another study on anti-CTLA4, treatment of metastatic melanoma patients’ taxa belonging to Bacteroidetes phylum was correlated with resistance to ICB-induced colitis [12].”
BackgroundThe Microbiome in Advanced Melanoma: Where Are We Now?
Fortman, D. D., Hurd, D. E., & Davar, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01431-3 · Cited by 14
Miao, K., & Zhang, L. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.08.002 · Cited by 15
“73 , 74”
Zheng, Y., Li, L., Liu, X., Xu, S., Sun, X., Zhang, Z., Guo, H., & Shao, Q. (2023) · Industrial Crops and Products · doi:10.1016/j.indcrop.2023.117896 · Cited by 15
Khorashadizadeh, S., Abbasifar, S., Yousefi, M., Fayedeh, F., & Ghalibaf, A. M. (2024) · Cancer Reports · doi:10.1002/cnr2.70029 · Cited by 23
Management of gastrointestinal adverse events induced by immune‐checkpoint inhibitors
Wang, Z., & Shen, L. (2018) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.12.001 · Cited by 13
“The presence of baseline gut microbiota enriched with Firmicutes was associated with the more frequent occurrence of colitis, whereas patients with Bacteroidetes bacteria enrichment were resistant to colitis.(46,47) The use of antibiotics can alter the gut”
BackgroundToxicités immunologiques induites par les inhibiteurs de checkpoint en 2019 : mise au point
Comont, T., Bellière, J., Sibaud, V., Alric, L., Meyer, N., Mazières, J., Caron, P. J., Acket, B., Michot, J., Beyne‐Rauzy, O., et al. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.09.005 · Cited by 16
Cannarile, M. A., Gomes, B., Cañamero, M., Reis, B., Byrd, A. L., Charo, J., Yadav, M., & Karanikas, V. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2345 · Cited by 14
Mjaess, G., Karam, A., Aoun, F. Y., Albisinni, S., & Roumeguère, T. (2021) · Cancer · doi:10.1002/cncr.33893 · Cited by 14
“Moreover, a study with a multivariate analysis suggested that antibiotic therapy within the month before the administration of anti– PD- L1 treatments was associated with shorter PFS and OS in patients with advanced RCC.29 Derosa et al30 showed that overrepresentation of Akkermansia muciniphila, Bacteroides salyersiae…”
InfluentialThe interaction between gut microbiome and anti-tumor drug therapy.
Fu, C., Yang, Z., Yu, J., & Wei, M. (2021) · PubMed · Cited by 21
Han, H., Sun, Y., Fan, Y., Zhang, H., Yang, J., Chi, R., Gao, Y., Liu, J., Li, K., Li, W., et al. (2022) · Life · doi:10.3390/life12081262 · Cited by 13
Jiang, F., Zhang, Z., Chong, X., Shen, L., Fan, M., Liu, X., An, J., Peng, Z., & Zhang, C. (2022) · Cancers · doi:10.3390/cancers14174167 · Cited by 14
Roles of intestinal microbiota in response to cancer immunotherapy
Cong, J., & Zhang, X. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3374-8 · Cited by 13
Long, X., Kim, Y.-G., Pyo, Y., Yi, R., Zhao, X., & Park, K. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13488 · Cited by 13
Interaction between the breast tumor microenvironment and gut microbiome
Tang, G., Millar, E. K. A., Graham, P., & Beretov, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2514136 · Cited by 15
“249 Gopalakrishnan et al. 250 found the gut microbiome modulates a response to anti-PD-1 immunotherapy in melanoma patients through enhancing antigen presentation or increasing T cell recruitment to the TME.”
Li, Z., Xie, Y., Wang, T., Liu, Y., Tian, Y. E., & Hua, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631273 · Cited by 14
“Firstly, the administration of dICI can disrupt the balance of the intestinal microbiota, leading to the activation of T helper 1 and 17 cells, which subsequently results in in fl ammation of the intestinal mucosa (41, 42).”
Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy
Tian, M., Zhang, S., Tseng, Y., Shen, X., Dong, L., & Xue, R. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210706110713 · Cited by 12
Diet Influences Immunotherapy Outcomes in Cancer Patients: A Literature Review
Kian, N., Behrouzieh, S., Razi, S., & Rezaei, N. (2022) · Nutrition and Cancer · doi:10.1080/01635581.2022.2133151 · Cited by 13
“Researchers have found a correlation between the abundance of Bacteroidetes species and a lower likelihood of developing colitis in immunotherapy receivers (102).”
BackgroundVogrig, A., Dentoni, M., Florean, I., Cellante, G., Domenis, R., Iacono, D., Pelizzari, G., Rossi, S., Damato, V., Fabris, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548897 · Cited by 23
“Bacteria belonging to the Bacteroidetes phylum have been demonstrated to be protective against the development of ICI-related colitis in metastatic melanoma patients treated with anti-CTLA-4 (57, 58), though possibly correlating with a poorer oncological outcome (57).”
Probiotics Behavior‐Inspired Biomimetic Platform for Ulcerative Colitis Prevention and Therapy
Wang, M., Nian, L., Zhang, S., Zeng, Y., Man, W., Sun, X., Wang, S., & Cao, C. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202505817 · Cited by 24
Fan, R., Zhang, W., Wang, L., Tao, F., Xiao, J., & Wang, L. (2025) · Foods · doi:10.3390/foods14162910 · Cited by 12
“On the other hand, inflammation can be suppressed by reducing butyric acid and the bacteria that produce butyric acid [64], and inflammation itself was closely linked to obesity [65].”
Gomez‐Alvarez, V., & Revetta, R. P. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.571009 · Cited by 12
“For example, sequencing methods targeting 16S rRNA regions have allowed identification of microbiome-associated bioindicators that correlate with protection against CTLA-4 blockade-associated colitis (Dubin et al., 2016), presence of adenomatous polyps in patients (Hale et al.”
BackgroundThe impact of modulating the gastrointestinal microbiota in cancer patients
Morkūnas, E., Skiecevičienė, J., & Kupčinskas, J. (2020) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2020.101700 · Cited by 14
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Pezeshki, P. S., Sharif, P. M., & Rezaei, N. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1929919 · Cited by 14
“These risk factors constitute preexisting autoimmune disorders [38], pre-inflammation microbiome composition [39], or”
BackgroundKnippel, R. J., & Sears, C. L. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7062 · Cited by 14
“Enrichment of bacteria containing vitamin B biosynthesis pathways and polyamine transport were associated with immune checkpoint inhibitor–associated colitis.(45) Interestingly, the varied composition of the microbiome correlates with both positive and negative immunotherapeutic responses.”
BackgroundAn Insight into the Clinical Application of Gut Microbiota during Anticancer Therapy
Li, W., & Chen, T. (2022) · Advanced Gut & Microbiome Research · doi:10.1155/2022/8183993 · Cited by 16
“In accord with this notion, it is also demonstrated in another research that the Bacteroides overrepresentation is the reason for ameliorated degree of CTLA-4-blockadeinduced colitis [38].”
ResultCheckpoint Inhibitors and the Gut
Tran, T., Tran, N. G. T., & Ho, V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030824 · Cited by 12
“Bacteroides have been shown to produce riboflavin metabolites which could potentially activate innate T-regulatory cells within the mucosa, thus promoting immune tolerance in the GIT [9].”
BackgroundInfluentialIncreased Response to Immune Checkpoint Inhibitors with Dietary Methionine RestrictionPreprint
Morehead, L. C., Garg, S., Wallis, K., Siegel, E. R., Tackett, A. J., & Miousse, I. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.05.535695 · Cited by 12
Han, X., Zang, D., Liu, D., & Chen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988849 · Cited by 12
Reid, P. D., Sandigursky, S., Song, J., Lopez-Olivo, M. A., Safa, H., Cytryn, S. L., Efuni, E., Buni, M., Pavlick, A. C., Krogsgaard, M., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2261264 · Cited by 15
Systemic metabolic depletion of gut microbiome undermines responsiveness to melanoma immunotherapy
Zakharevich, N. V., Morozov, M. D., Kanaeva, V. A., Filippov, M. S., Zyubko, T., Ivanov, A. B., Игоревич, У. В., Klimina, K. M., & Olekhnovich, E. I. (2024) · Life Science Alliance · doi:10.26508/lsa.202302480 · Cited by 12
“Notably, the intestine microbiome has been found to be associated not only with the ICT response but also with the incidence of related side effects (Dubin et al, 2016; Li et al, 2019).”
BackgroundYu, Z., Wang, Q., Wang, Z., Liu, S., Xia, T., Duan, C., Liu, Y., Ding, X., Chen, S., Yu, T., et al. (2024) · Head & Neck · doi:10.1002/hed.27917 · Cited by 14
Challenging Cases: Management of Immune-Related Toxicity
Weber, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_209557 · Cited by 10
Bairi, K. E., Jabi, R., Trapani, D., Boutallaka, H., Bencheikh, B. O. A., Bouziane, M., Amrani, M., Afqir, S., & Maleb, A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1758063 · Cited by 12
“In this perspective, a prospective study which enrolled patients with advanced melanoma (n = 34) and treated with ipilimumab from the Memorial Sloan Kettering Cancer Center (USA) demonstrated that increased abundance of Bacteroidetes phylum in stool samples correlates with adverse outcomes following anti-CTLA-4 treatm…”
BackgroundInfluentialMicNet toolbox: Visualizing and unraveling a microbial network
Favila, N., Madrigal‐Trejo, D., Legorreta, D., Sánchez-Pérez, J., Espinosa-Asuar, L., Eguiarte, L. E., & Souza, V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0259756 · Cited by 12
Seguí, E., Zamora, C., Barreto, T. D., Padrosa, J., Viladot, M., & Marco‐Hernández, J. (2022) · Diagnostics · doi:10.3390/diagnostics12092116 · Cited by 10
“In two retrospective studies, a higher relative abundance of the Bacteroidetes phylum was shown to be associated with a reduced rate of ipilimumab-induced colitis [20,21].”
BackgroundGüven, D. C., Şahin, T. K., Rizzo, A., Ricci, A. D., Aksoy, S., & Şahin, K. (2022) · Applied Sciences · doi:10.3390/app122010548 · Cited by 11
“(2016) [84] Melanoma/34 Lower risk of colitis in Bacteroides spp.”
BackgroundCurrent landscape and tailored management of immune-related adverse events
Liu, W., Luo, Z., Liu, Y., & Sun, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078338 · Cited by 10
Jaeghere, E. A. D., Hamerlinck, H., Tuyaerts, S., Lippens, L., Nuffel, A. M. T. V., Baiden-Amissah, R. E. M., Vuylsteke, P., Henry, S., Trinh, X. B., van Dam, P. A., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.10.020 · Cited by 12
Lactobacillus gasseri prevents ibrutinib-associated atrial fibrillation through butyrate
Shi, L., Duan, Y., Fang, N., Zhang, N., Yan, S. R., Wang, K., Hou, T., Wang, Z., Jiang, X., Gao, Q., et al. (2025) · EP Europace · doi:10.1093/europace/euaf018 · Cited by 11
Expanding horizons of cancer immunotherapy: hopes and hurdles
Sonar, P. V., Singh, A. K., Mandadi, S., & Sharma, N. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1511560 · Cited by 12
Bangolo, A., Amoozgar, B., Habibi, M., Simms, E., Nagesh, V. K., Wadhwani, S., Wadhwani, N., Auda, A., Eliáš, D., Mansour, C., et al. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i2.105375 · Cited by 11
Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?
Pu, X., Chao, G., Dong, L., & Chang, P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1739794 · Cited by 11
“Referring to ICI-associated toxicity, it has been revealed that patients with a higher fecal level of Bacteroidales commonly exhibit lower incidences of colitis than those with lower levels.(23) Conversely, cancer patients who have used antibiotics long term have not only a poor response to ICI therapy but also an inc…”
BackgroundMicrobiome diversity predicts surgical success in patients with rectovaginal fistula
Leach, D. A., Chen, J., Yang, L., Chua, H. K., Walther-Antonio, M. R. S., & Occhino, J. A. (2020) · International Urogynecology Journal · doi:10.1007/s00192-020-04580-2 · Cited by 12
Neuville, C., Aubin, F., Puzenat, E., Popescu, D., Crépin, T., & Nardin, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032844 · Cited by 11
Intestinal Bacteria Encapsulated by Biomaterials Enhance Immunotherapy
Liu, Y., Li, Z., Wu, Y., Jing, X., Li, L., & Fang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620170 · Cited by 12
“compared the composition of preinflammation fecal microbiota before and after the development of colitis (65).”
Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
Kaneoka, A., Okada, E., Sugino, H., Saito‐Sasaki, N., Omoto, D., & Nakamura, M. (2022) · Diagnostics · doi:10.3390/diagnostics12020480 · Cited by 11
Checkpoint Inhibitors and Induction of Celiac Disease-like Condition
Lerner, A., & Benzvi, C. (2022) · Biomedicines · doi:10.3390/biomedicines10030609 · Cited by 10
“Furthermore, variation in gastrointestinal flora was found to play a role in host immunity [79], and certain alterations in gut microbiome composition of metastatic melanoma patients who went through ipilimumab therapy were found to increase the risk to develop ICPi’s induced colitis [80,81].”
BackgroundWang, X., Wu, C., & Wei, H. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0039 · Cited by 9
“The first prospective study to characterize the composition of gut microbiota before the development of CTLA-4 blockade-induced new-onset colitis demonstrated that members of the Bacteroidetes phylum were correlated with resistance to colitis in a subset of patients (Dubin et al, 2016).”
Limeta, A., Gatto, F., Herrgård, M. J., Ji, B., & Nielsen, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.07.032 · Cited by 9
“An early study aiming to identify stool biomarkers for ICI induced colitis performed metagenomic profiling of 34 prospectively enrolled melanoma patients and reported higher abundances of bacteria belonging to the Bacteroidetes phylum in patients that did not experience colitis [94].”
BackgroundYan, S., Yu, L., Tian, F., Zhao, J., Chen, W., & Zhai, Q. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250205 · Cited by 12
Exploring the etiology of colitis: insights from gut microbiota research
Qian, G., Chen, X., Liu, G., Yu, J., Zhong, S.-J., Yang, J., Sun, Y., & Zhou, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2512010 · Cited by 13
“204 Intervention strategies show that Bifidobacterium inhibits inflammation by amplifying regulatory T cells, while the tryptophan metabolite indole-3-carbaldehyde maintains epithelial integrity by activating the AhR/IL-22 pathway.”
Wang, D., He, H., Li, X., & Wang, Z. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4535 · Cited by 9
“(22) sequenced the bacterial flora of 34 melanoma patients and found that those with melanoma rich in Bacteroidetes had a lower incidence of colitis after the application of the CTLA-4 blocker ipilimumab.”
BackgroundRole of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer
Shi, L., Xu, Y., & Feng, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07689-0 · Cited by 9
Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota
Wei, Y., Song, D., Wang, R., Li, T., Wang, H., & Li, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1038710 · Cited by 9
“Similarly, previous study showed that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species, as T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade (81).”
BackgroundResultInfluentialHarnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
Gabrielli, G., Shouval, R., Ghilardi, G., van den Brink, M. R. M., & Ruella, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000950 · Cited by 11
Liu, B., Liu, Z., Jiang, T., Gu, X., Yin, X., Cai, Z., Zou, X., Dai, L., & Zhang, B. (2024) · European journal of medical research · doi:10.1186/s40001-024-01741-7 · Cited by 13
“However, consensus on the core microbial drivers or protective microbes of irAEs is still lacking, due to inconsistent findings reported in previous studies [11, 17–19].”
BackgroundResultRôle du microbiote intestinal dans la réponse aux thérapies anti-tumorales
Vétizou, M., Daillère, R., & Zitvogel, L. (2017) · Biologie Aujourd hui · doi:10.1051/jbio/2017009 · Cited by 10
The good, the (not so) bad and the ugly of immune homeostasis in melanoma
Duarte, J. D. G., Woods, K., Andrews, M. C., & Behren, A. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12001 · Cited by 11
“Similarly, the risk of developing colitis following CTLA-4 blockade was associated with lower abundance of Bacteroidetes organisms and under-representation of distinct microbial biochemical pathways.(41) What is not clear at this stage is whether dysbiosis necessarily precedes cancer development, and the qualitative a…”
BackgroundScience in Focus: The Microbiome and Cancer Therapy
Alexander, J. L., Kohoutová, D., & Powell, N. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.09.004 · Cited by 11
The Impact of the Fecal Microbiome on Cancer Immunotherapy
Osman, A. E. G., & Luke, J. J. (2019) · BioDrugs · doi:10.1007/s40259-018-0328-8 · Cited by 9
Impact of genetic factors on platinum-induced gastrointestinal toxicity
Zheng, Y., Deng, Z. H., Tang, M., Xiao, D., & Cai, P. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108324 · Cited by 10
Wong, M., Barbulescu, P., Coburn, B. A., & Reguera-Nuñez, E. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104804 · Cited by 9
Qu, Y., Wang, Z., Feng, J., Wang, L., Liu, H., Liu, D., Zhao, Y., Yu, R., Li, W., Sun, D., et al. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-858 · Cited by 8
“ICI-related gastroenteritis often causes the interruption of immunotherapy, and a small number of serious cases may be related to the direct suppression of T cell activation by immunotherapy and specific microbiota in the intestine (64-67).”
BackgroundPark, B. J., Stone, C. A., Dewan, A. K., & Johnson, D. B. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.12.006 · Cited by 11
Kuusisalo, S., Koivunen, J. P., & Iivanainen, S. (2022) · Cancers · doi:10.3390/cancers14092276 · Cited by 10
Zheng, L., Yang, X., Wei, Y., You, J., Li, H., Liao, J., & Cheng, Y. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110738 · Cited by 9
Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients
Mathew, A., Shatila, M., Lai, Z., Tan, D., Oliva, I. C. G., Wang, J., Alhalabi, O., Zhang, H. C., Thomas, A. S., & Wang, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04367-6 · Cited by 11
Gastrointestinal toxicity of systemic oncology immunotherapy
Bureš, J., Kohoutová, D., & Zavoral, M. (2022) · Klinicka onkologie · doi:10.48095/ccko2022346 · Cited by 9
“Na základě sekvenování 16S rRNA, Dubin et al. [65] zjistili, že pacienti s vyšším za stoupením bakterií kmene Bacteroidetes ve střevních mikrobio tech měli menší ri ziko vzniku kolitidy (indukované ipili mumabem).”
Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends
Asmar, N. E., Ibrahim, T., & Rey, J. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5188-z · Cited by 9
“Nonetheless, combining the polyamine transport system and vitamin production in assessing the risk of developing colitis in CPIs-treated patients resulted in 70% sensitivity and 83% specificity [1, 16], findings confirmed by Dubin et al.”
ResultNutrition, Immunity, and Cancer
Ghaedi, E., Rezaei, N., & Mahmoudi, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-16073-9_12 · Cited by 9
Recognition and management of the gastrointestinal and hepatic immune‐related adverse events
Tan, B., Li, Y., Xu, Y., Chen, M., Wang, M., & Qian, J. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13317 · Cited by 9
The Microbiome in Immuno-oncology
Toker, J. S., Arora, R., & Wargo, J. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_19 · Cited by 12
Cruellas, M., Yubero, A., Zapata, M., Galvez, E. M., Ruiz, M. G., Isla, D., Lastra, R., Martínez‐Lostao, L., Ocariz, M., Pardo, J., et al. (2021) · Infection and Immunity · doi:10.1128/iai.00665-20 · Cited by 12
“ulate T-regulatory cell differentiation and limit inflammation (21).”
BackgroundFurther evidence to support judicious use of antibiotics in patients with cancer
Luke, J. J., & Pal, S. K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy153 · Cited by 9
Chen, J., Xiao, Y., Wang, K., Fu, X., Fan, Y., Hossen, M. J., Chen, Y., Bai, W., Yu, Z., & Xu, B. (2024) · Food Frontiers · doi:10.1002/fft2.344 · Cited by 9
Tamura, K., Okuma, Y., Nomura, S., Fukuda, A., Masuda, K., Matsumoto, Y., Shinno, Y., Yoshida, T., Goto, Y., Horinouchi, H., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05649-x · Cited by 9
“…blockers; PS, Eastern Cooperative Oncology Group performance status; SQC, squamous cell carcinoma; Tmax, maximum tumor size at the start of induction therapy have been found to promote anti-tumor immune responses and confer resistance to immune-related colitis (Dubin et al. 2016).”
BackgroundJia, W., Deng, Z., Papini, M. P., Cheng, L., Jin, N., Zhang, D., Li, Z., Zhang, D., Zhu, Y., & Ding, A. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.137239 · Cited by 8
Di, X., Shí, X., Gai, F., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1621045 · Cited by 11
“( 5) Speci fi c gut microbiota modulate immune and nervous system functions, thereby in fl uencing the pathophysiological processes associated with neuroin fl ammation and neural injury (32, 33).”
Mechanistic and therapeutic advances in immune-mediated gastrointestinal disorders
Garabatos, N., Angelats, E., & Santamaría, P. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.07.024 · Cited by 8
Jia, R. F., Xiao, C., Zhang, Y., Hu, L.-Y., Jun-jun, Y., Zuo, R., Hu, Y., Xie, Y.-H., Ma, X., Li, Q., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101311 · Cited by 11
Meng, C., Wang, X., Fan, L., Fan, Y., Yan, Z., Wang, Y., Li, Y., Zhang, J., & Lv, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115588 · Cited by 8
Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies
Verhaert, M., & Aspeslagh, S. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114235 · Cited by 11
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma
Esmaeli, B., Ogden, T., Nichols, M., Lu, T. J., Debnam, J. M., Dimitriou, F., McQuade, J. L., & Oliva, I. C. G. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000001016 · Cited by 10
Menon, T., & Afzali, A. (2019) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-019-00263-0 · Cited by 9
Gastrointestinal disorders as immune-related adverse events
Balducci, D., Quatraccioni, C., Benedetti, A., Marzioni, M., & Maroni, L. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00039 · Cited by 10
“The authors showed that members of Bacteroidetes phylum were linked to worse cancer outcome and lower incidence of immune-related colitis, whereas Firmicutes were associated with better cancer response and enterocolitis occurrence [52].”
BackgroundPathology of drug hypersensitivity reactions and mechanisms of immune tolerance
Thomson, P., Hammond, S., & Naisbitt, D. J. (2022) · Clinical & Experimental Allergy · doi:10.1111/cea.14235 · Cited by 11
The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment
Sági, V., Makra, N., Csoszánszki, N., Decmann, Á., Szabó, D., & Garami, M. (2022) · Antibiotics · doi:10.3390/antibiotics11111521 · Cited by 12
“, reduction, hydrolysis, dealkylation, dehydroxylation) that can be used in drug metabolism [26,31].”
BackgroundTargeting microbiome, drug metabolism, and drug delivery in oncology
Sumiyoshi, A., Fujii, H., & Okuma, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114902 · Cited by 9
Li, M., Li, N., Dong, Y., Zhang, H., Bai, Z., Zhang, R., Fei, Z., Zhu, W., Xiao, P., Sun, X. S., et al. (2024) · World Allergy Organization Journal · doi:10.1016/j.waojou.2024.100897 · Cited by 8
“33 , 34 Lachnospiraceae UCG-001 35 and Ileibacterium , 36 which can produce SCFAs, have been reported to be bene fi cial against in fl ammation.”
Grover, S., & Srivastava, A. (2019) · Cancer · doi:10.1002/cncr.32005 · Cited by 8
“However, immune check point inhibitors can cause a variety of systemic and organspecific immunerelated adverse events by mechanisms that are unclear.(4,5)”
BackgroundPredictive Values of Colon Microbiota in the Treatment Response to Colorectal Cancer
Ros, J. G., Ramos-Arenas, V., & Conesa‐Zamora, P. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0044 · Cited by 9
Toxicities and outcomes: Do steroids matter?
Johnson, D. B. (2018) · Cancer · doi:10.1002/cncr.31627 · Cited by 8
The Anti- and Pro-Tumorigenic Role of Microbiota and Its Role in Anticancer Therapeutic Strategies
Greco, G., Zeppa, S. D., Agostini, D., Attisani, G., Stefanelli, C., Ferrini, F., Sestili, P., & Fimognari, C. (2022) · Cancers · doi:10.3390/cancers15010190 · Cited by 9
Emerging Noninfectious Indications for Live Biotherapeutic Products in Gastroenterology
Newman, K. L., & Allegretti, J. R. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002584 · Cited by 10
Jiang, Q., & Xue, R. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i3.577 · Cited by 7
“Specifically, factors such as pre-existing autoimmune disease[14-18], sex and body mass index[19-22], response to ICI[5,23-28], circulating cytokines and immune cells[19,29-31], inherited genetic variants[32,33], and microbiome[34-36] have been previously implicated in the prediction of irAEs.”
Cruz, C. C., Santos, M. J. M. N., Wali, S., Varatharajalu, K., Thomas, A. S., & Wang, Y. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2473305 · Cited by 9
Shatila, M., Devalaraju, S. S., Takigawa, K., Catinis, C., Lee, I. J.-A., Baerman, E. A., Ngo, S., Mittal, N., Glombicki, S. E., Machado, A. P., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.7023 · Cited by 10
Steroid-sparing strategies for managing immune-related adverse events
Huang, J. J., Yousefiasl, M., Singh, N., Grivas, P. D., & Bhatia, S. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013776 · Cited by 8
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.